Mechanisms of Drug Abuse Interactions with HIV Neuropathogenesis (R01)

The summary for the Mechanisms of Drug Abuse Interactions with HIV Neuropathogenesis (R01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Mechanisms of Drug Abuse Interactions with HIV Neuropathogenesis (R01): -Purpose. This Funding Opportunity Announcement (FOA) solicits research grant applications to examine the mechanisms of interaction between licit or illicit substance abuse, or medications to treat substance abuse, and events related to the etiology and pathogenesis of HIV-associated neurologic complications. -Mechanism of Support. This FOA will utilize the R01 grant mechanism and runs in parallel with an FOA of identical scientific scope, RFA-DA-07-003, that solicits applications under the R21 mechanism. -Funds Available and Anticipated Number of Awards. NIDA intends to commit $3 million dollars in FY 2007 to fund 5 to 10 new grants in response to this RFA and its companion RFA (DA-07-003). Competing supplements will be accepted. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. Competing supplements to NIDA R01 human subjects research project grants will be accepted, if there will be at least 2 years remaining at the time of award. Requests for supplements may not exceed $150,000 direct costs per year, and the duration cannot exceed the remaining duration of the parent grant.

Federal Grant Title:	Mechanisms of Drug Abuse Interactions with HIV Neuropathogenesis (R01)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Education Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-DA-07-002
Type of Funding:	Grant
CFDA Numbers:	93.279
CFDA Descriptions:	Drug Abuse and Addiction Research Programs
Current Application Deadline:	No deadline provided
Original Application Deadline:	Mar 22, 2007
Posted Date:	Nov 20, 2006
Creation Date:	Nov 20, 2006
Archive Date:	Apr 21, 2007
Total Program Funding:	$3,000,000
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: Private institutions of higher education For profit organizations other than small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled "Additional Information on Eligibility" for clarification) Special district governments Native American tribal organizations (other than Federally recognized tribal governments) City or township governments Public housing authorities/Indian housing authorities Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) County governments Independent school districts State governments
Additional Information on Eligibility: Foreign institutions are eligible to apply. Eligible agencies of the Federal Government can apply. Faith-based or community-based organizations can apply.
Link to Full Grant Announcement: Information not provided
Grant Announcement Contact: NIH OER Webmaster
[email protected]
[email protected] If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...; • Education Activities for Responsible Analyses of Complex, Large-Scale Data (R25- Clinical ...; • Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Tr...; • Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Tr...; • Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial option...; • NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards; • Drug Abuse Aspects of Hiv/Aids and Other Infections; • Epidemiology of Drug Abuse
More Grants from the National Institutes of Health: • SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies...; • Small Business Transition Grant For Early Career Scientists (R41/R42 Clinical Trial Not Al...; • Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional); • Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial No...; • Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimenta...